Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma

British Journal of Cancer

Volumn 90, Issue 1, 2004, Pages 65-69

  Mabed, M ^a   El Helw, L ^a   Shamaa, S ^a  

^a MANSOURA UNIVERSITY   (Egypt)

Author keywords

Chemotherapy; Hepatocellular carcinoma; Phase II; Viscum fraxini 2

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; ANTINEOPLASTIC AGENT; ASCORBIC ACID; DISODIUM HYDROGEN PHOSPHATE; UNCLASSIFIED DRUG; VISCUM ALBUM EXTRACT; VISCUM FRAXINI 2; WATER;

ADULT; AGED; AMPOULE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DILUTION; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SCREENING; ERYTHEMA; FEMALE; FEVER; FRAXINUS; HEMATOLOGIC DISEASE; HUMAN; INJECTION PAIN; LIVER CELL CARCINOMA; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; VISCUM ALBUM;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, HEPATOCELLULAR; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; INJECTIONS, SUBCUTANEOUS; LIVER NEOPLASMS; MALE; MIDDLE AGED; PHYTOTHERAPY; PLANT EXTRACTS; TREATMENT OUTCOME; VISCUM ALBUM;

EID: 0842286830     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6601463     Document Type: Article

References (42)

1. Becker H (1986) Botany of European mistletoe (Viscum album L.). Oncology 43: 2-7
2. Beuth J, KO HL, Tungal L, Steuer MK, Geisel J, Jeljaszewics J, Pulverer G (1993) Das lektin der mistel als immunomodulatoe in der adjuvanten tumortherapie. Detsche zeitschrift fur onkologie 25(3): 73-76
3. Bosch FX, Munoz N (1991) Hepatocellular carcinoma in the world: epidemiologic questions in etiology, pathology and treatment of hepatocellular carcinoma in North America. In: Tabor E, DiBisecglie AM, Purcell RH, (eds) Advances in the Applied Biotechnology Series, pp 35-54
4. Chao Y, Chan WK, Birkhofer MJ, Hu OPY, Wang SS, Huang YS, Liu M, Whang-Peng J, Chi KH, Lui WY, Lee SD (1998) Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma. Br J Cancer 78(1): 34-39
5. Dexter DL, Leith JT (1986) Tumor heterogeneity and drug resistance. J Clin Oncol 4: 244-257
6. Falkson G, Burger W (1995) A phase II trial of Vindesine in hepatocellular carcinoma. Oncology 52: 86-87
7. Hajto T, Hostanska K, Frei K, Rohrdorf C, Gabius HJ (1990) Increased secretion of tumor necrosis factor-α, interleuldn-1, and interleukin-6 by human mononuclear cells exposed to B-galactosid-specific lectin from clinically applied mistletoe extract. Cancer Research 50: 3322-3326
8. Hamprecht K, Handgretinger R, Voetsch W, Anderer FA (1987) Mediation of human NK-activity by components in extracts of viscum album. Int J Immunopharmacol 9: 199-209
9. Hartmann S, Scheffler A, Lessmann M (1995) A vesicle fraction of mistletoe induces T cell proliferation of sensitized lymphocytes in patients treated with mistletoe extracts. Beitrag Zur Tagung Der Immunologischen Gesellschaft: Regensburg
10. Huang C, Wu M, Xu G, LiDZ, Cheng H, Tu ZX, Jiang HO, Gu JR (1992) Overexpression of the MDRI gene and P-glycoprotein in human hepatocellular carcinoma. J Natl Cancer Inst 84: 262-264
11. Janssen O, Scheffler A, Kabelitz D (1993) In vitro effects of mistletoe extracts and mistletoe lectins: Cytotoxicity towards tumor cells due to the induction of programmed cell death (apoptosis). Arzneimittel Forschung, Drug-Research 43(11): 1221-1227
12. Kaplan EM, Meier P (1959) Non parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481
13. Kienle GS, Berrino F, Bussing A, Portalupi E, Rosenzweig S, Kiene H (2003) Mistletoe in cancer - a systematic review on controlled clinical trials. Eur J Med Res 8(3): 109-119
14. Koehler R (1992) Verfahren und vorrichtung zur herstellung wassriger kolloide. Europaisches Patent Nr. 0310984
15. Lai ECS, Choi TK, Cheng CH, Mok FP, Fan ST, Tan ES, Wong J (1990) Doxorubicin for unresectable hepatocellular carcinoma. A prospective study on the addition of verapamil. Cancer 66: 1685-1687
16. Lai CI, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. Cancer 62: 479-483
17. Lankish PG, Vogt W (1978) Potentiation of hemolysis by the combined action of phospholipase A and a basic peptide containing s-s bonds (viscotoxin B). Experientia 27(2): 122-123
18. Lee NW, Wong J, Ong GB (1982) The surgical management of primary carcinoma of the liver. World J Surg 6: 66-75
19. Lin J, Shiu W, Leung WT, Tao M, Leung N, Lau WY, Li AK (1993) Phase II study of high dose Ifosfamide in hepatocellular carcinoma. Cancer Chemotherapy Pharmacol 31: 338-339
20. Lotze MT, Flickinger JC, Carr BJ (1993) Hepatobiliary system. In: DeVita VT, Hellman S, Rosenberg SA, (eds) Cancer: principles and practice of oncology, ed 4. pp 883-914. Philadelphia: J.B. Lippincott
21. Luther P, Becker H (1987) Die Mistel. Berlin: Spring Verlag
22. Miller AB, Hoogstraten B, Ataquet M (1981) Reporting results of cancer treatment. Cancer 47: 207-214
23. Mueller EA, Anderer FA (1990) Synergistic action of a plant rhamnogalacturonan enhancing antitumor cytotoxicity of human natural killer and lymphokin - activated killer cells: chemical specificity of target cell recognition. Cancer Research 50: 3646-3651
24. Mueller EA, Hamprecht K, Anderer FA (1989) Biochemical characterization of a component in extracts of viscum album enhancing human NK cytotoxicity. Immunopharmacology 17: 11-18
25. Okada S, Okazaki N, Nose H, Shimada Y, Yoshimori M, Aoki K (1993) A phase 2 study of cisplatin in patients with hepatocellular carcinoma. Oncology 50: 22-26
26. Okuda K (1980) Primary liver cancer in Japan. Cancer (Phila.) 45: 2663-2672
27. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer (phila.) 56: 918-928
28. O'Reilly E, Stuart K, Kemeny N, Steger C, Raeburn I, Sanz-Altamira P (1998) A phase II trial of irinotecan (CPT-II) in patients with advanced hepatocellular carcinoma. Proc Am Soc Clin Oncol 267: 1026
29. Ribereau-Gayon G, Jung ML, Baudino S, Salle JP (1986) Effects of mistletoe (Viscum album L.) extracts on cultured tumor cells. Experientia 42: 594-599
30. Rougier P, Ducreux M, Kerr D, Carr BI, Francois E, Ednis A, Seymour L (1997) A phase II study of raltitrexed (Tomudex) in patients with hepatocellular carcinoma. Ann Oncol 8: 500-502
31. Scheer R (1996) Sicherung der pharmazeutischen Qualitat von mistelpraparaten. In: R. Scheer, H. Becker, PA Berg (Ed) Grundlagen der Misteltherapie, pp 139-150. Stuttgart: Hippokrates Verlage
32. Schrader-Fischer G, Apel K (1993) The anticyclic timing of leaf senescence in the parasitic plant viscum album is closely correlated with the selective degradation of sulfur-rich viscotoxin. Plant physiology 101: 745-749
33. Schultze JL, Stettin A, Berg PA (1991) Demonstration of specifically sensitized lymphocytes in patients treated with an aqueous mistletoe extract (Viscum album L.). Klinische Wochenschrift 69: 397-403
34. Steiner R (1961) Vortrag vom 2. 4. 1920; Geisteswissenschaft und Medizin GA 312, pp 246-262. Dornach: Verlag der Rudolf Steiner NachlaBverwaltung
35. Stuart K, Tessitore J, Rudy J, Clendennin N, Johnston A (1999) A phase II trial of nolatrexed dihydrochloride in patients with advanced hepatocellular carcinoma. Cancer 86: 410-414
36. Urech K, Schaller G, Giannattasio M (1996) Bioassay zur bestmmung von viscotoxinen. In: Scheer R, Becker H, Berg PA (eds) Grundlagen der mistletherapie, pp 111-118. Stutgart: Hippokrates Verlag
37. Venook AP (1994) Treatment of hepatocellular carcinoma: Too many options? J Clin Oncol 12: 1232-1234
38. Whang-Peng J, Chao Y (1998) Clinical trials of hepatocellular carcinoma in Taiwan. Hepatogastroenterology 45(24): 1937-1943
39. Wierzbicki R, Ezzat A, Abdel-Warith A, Ayoub A, Kagevi I, Fadda M, Siech J, Abdul Kareem M, Amin T, Yazigi A (1994) Phase II trial of chronic daily VP 16 administration in unresectable hepatocellular carcinoma (HCC). Ann Oncol 5: 466-467
40. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. Geneva: WHO Offset Publications
41. Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, Shimado Y (1988) Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 24: 1897-1898
42. Zarkovic N, Vukovic T, Loncaric I, Miletic M, Zarkovic K, Borovic S, Cipak A, Sabolovic S, Konitzer M, Mang S (2001) An overview on anticancer activities of the vsicum album extract Isorel. Cancer Biother Radiopharm 16: 55-62